Investment
Features
FeesSafety
Academy
More
Pluang+

Canagold successfully produces refined antimony metal from its New Polaris project, boosting value potential.

Market News
06 Oct 2026
Newsfile Corp
View Source
Bullish
Canagold successfully produces refined antimony metal from its New Polaris project, boosting value potential.

Canagold Resources has achieved a key milestone by producing physical antimony metal with over 99% purity from its New Polaris gold-antimony concentrate in British Columbia. This breakthrough shows the project can deliver refined antimony metal, not just concentrate, allowing the company to capture more value and supply critical metal directly to North American markets. Antimony is a critical mineral with limited global refining capacity, mostly controlled by China, making this development important for secure supply chains. Canagold plans further testing and commercial planning to optimize production and integrate antimony metal into its project model.

Canagold Resources' milestone in producing over 99% pure antimony metal comes as a backdrop to the Basic Materials sector's activity on Pluang. As of Oct 06, 2026 18:11 WIB, 19 of 38 priced US Basic Materials stocks rose while 13 fell. Notable movers include Standard Lithium Ltd (SLI) at USD 1.75 with a 1-day change of +1.74% and a typical hold time of 22 days, AngloGold Ashanti Limited (AU) at USD 93.20 with 0% sell and 100% buy order activity, and Harmony Gold Mining Co. (HMY) at USD 17.07 with 73% sell and 27% buy order activity.

More News

Costco shares drop 10% in 6 months while S&P 500 rises 17%, raising value questions below $900.

Costco shares drop 10% in 6 months while S&P 500 rises 17%, raising value questions below $900.

Over the past six months, Costco's stock has fallen by 10%, contrasting with the S&P 500's 17% gain. This decline has sparked debate on whether Costco's shares, now trading under $900, represent a buying opportunity. Investors are weighing if the pri...

Analyst Insights
Neutral
3 hours ago
OKYO Pharma starts Phase 3 trial for neuropathic corneal pain drug urcosimod

OKYO Pharma starts Phase 3 trial for neuropathic corneal pain drug urcosimod

OKYO Pharma has enrolled the first patients in its Phase 3 NEPTUNE trial testing urcosimod for neuropathic corneal pain, a severe eye condition with no FDA-approved treatment. The trial has begun in the US and will expand to Europe, with patients rec...

Market News
Bullish
4 hours ago
Wall Street agrees on 5 dividend stocks yielding 5%+ for reliable passive income.

Wall Street agrees on 5 dividend stocks yielding 5%+ for reliable passive income.

Wall Street analysts have reached a rare consensus on five dividend stocks yielding 5% or more, seen as strong buys for dependable passive income. These stocks—Amcor, Energy Transfer, International Paper, Mid-America Apartment Communities, and Verizo...

Analyst Insights
Bullish
4 hours ago
OKX secures $25B valuation in funding round with QRT, Circle, Ripple, and SC Ventures backing

OKX secures $25B valuation in funding round with QRT, Circle, Ripple, and SC Ventures backing

Crypto exchange OKX has maintained its $25 billion valuation in a new funding round featuring Qube Research & Technologies (QRT), Circle, Ripple, and Standard Chartered’s SC Ventures. The fresh capital will help OKX enhance its market infrastructure ...

Market News
Bullish
4 hours ago
Meta tests full-screen video-first Facebook app in India, focusing on Reels to boost video engagement.

Meta tests full-screen video-first Facebook app in India, focusing on Reels to boost video engagement.

Meta has started testing a new Facebook user experience in India that opens the app directly into full-screen video, highlighting Reels. This test aims to create a more immersive, video-centric experience and follows Meta's broader strategy to priori...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App